Achieve Life Sciences, Inc.

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.achievelifesciences.com

Market Cap $142.82M
PE -4
Debt $9.82M
Cash $9.54M
EV $143.10M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$32.94M
ROE	-105%
Equity	$31.38M
Growth Stability	1
PE	-4.34
PB	4.55
Price/Cash	0.07
Debt/Equity	0.31
Equity CAGR	-8%
Earnings Growth YoY	76%
Earnings Growth QoQ	48%
Equity CAGR 5Y	-13%
Equity CAGR 3Y	52%

Market Cap	$142.82M
Assets	$47.92M
Total Debt	$9.82M
Cash	$9.54M
Shares Outstanding	31.25M
EV	143.1M
Working Capital	38.81M
Current Ratio	6.78
Shares Growth 3y	38%
Equity Growth QoQ	-26%
Equity Growth YoY	677%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

SEC Filings

Direct access to Achieve Life Sciences, Inc. (ACHV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Achieve Life Sciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Achieve Life Sciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Achieve Life Sciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Achieve Life Sciences, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-	-	-	-	-	-
ROA	-	-6%	-138%	-66%	-78%	-37%	-70%	-141%	-154%	-
ROE	-	-106%	-134%	-80%	-91%	-40%	-118%	-510%	2K%	-105%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	0.53	1.94	-11.51	0.31
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.31)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	-23%	-47%	20%	29%	-10%	125%	28%	-30%	-
Equity YoY growth	-	-44%	-58%	101%	14%	107%	-25%	-70%	-117%	-13%
FCF YoY growth	-	-99%	-	-	43%	-12%	-	-	-	-